Zalevsky Jonathan
Nektar Therapeutics · Chief R&D Officer
Zalevsky Jonathan is listed in filings as Chief R&D Officer at Nektar Therapeutics. This profile follows SEC Form 4 activity through May 21, 2026, including sale activity. Recent filings connect the profile to Nektar Therapeutics (NKTR). The current snapshot covers public activity from Aug 20, 2024 to May 21, 2026. Reported amounts are shown as $13.0K to $137.9K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.
Latest Trades
| Company | Value | Action | Price | Last Price |
|---|---|---|---|---|
| $13k199 shares | SellMay 19, 2026 | $65.51 | $68.30 |